Early and late direct costs in a Southern African antiretroviral treatment programme: A retrospective cohort analysis

PLoS Medicine

Volumn 6, Issue 12, 2009, Pages

  Leisegang, Rory ^a   Cleary, Susan ^a   Hislop, Michael ^b   Davidse, Alistair ^a   Regensberg, Leon ^b   Little, Francesca ^a   Maartens, Gary ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b The Boulevard   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PATIENT COMPLIANCE; SOUTH AFRICA; STATISTICAL MODEL; TREATMENT DURATION; VIRUS LOAD; CONFIDENCE INTERVAL; ECONOMICS; RETROSPECTIVE STUDY; TIME;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; LINEAR MODELS; MALE; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SOUTH AFRICA; TIME FACTORS;

EID: 74049083781     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000189     Document Type: Article

References (33)

1. Levy AR, James D, Johnston KM, Hogg RS, Harrigan PR, et al. (2006) The direct costs of HIV/AIDS care. Lancet Infect Dis 6: 171-177.
2. Harling G, Wood R (2007) The evolving cost of HIV in South Africa: changes in health care cost with duration on antiretroviral therapy for public sector patients. J Acquir Immune Defic Syndr 45: 438-354.
3. Department of Health (2003) Operational plan for comprehensive HIV and AIDS care, management and treatment for South Africa. Available: www.info.gov.za/otherdocs/2003/aidsoperationalplan.pdf. Accessed 1 April 2008.
4. Rosen S, Vincent JR, MacLeod W, Fox M, Thea DM, et al. (2004) The cost of HIV/AIDS to businesses in southern Africa. AIDS 18: 317-324.
5. Regensberg L (1999) Aid for AIDS: an innovative solution. AIDS Anal Afr 9: 10-11.
6. (UNAIDS) JUNPoHA (2008) Report on the global AIDS epidemic. Geneva: UNAIDS.
7. (2007) HIV & AIDS and STI strategic plan for South Africa. Pretoria: South African National AIDS Council (SANAC). pp 1-136.
8. WHO (2006) Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access: recommendations for a public health approach. Geneva: World Health Organisation.
9. Regensberg L, Hislop M (2003) Aid for AIDS-A report back on more than four years of HIV/AIDS disease management in Southern Africa. South Afr J HIV Med 2: 7-10.
10. Ivers LC, Kendrick D, Doucette K (2005) Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41: 217-224.
11. Taverne B (2003) Free dispensing of antiretroviral treatments in Africa. Bull Soc Pathol Exot 96: 241-244.
12. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, et al. (2008) Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 86: 559-567.
13. Hellinger FJ, Fleishman JA (2000) Estimating the national cost of treating people with HIV disease: patient, payer, and provider data. J Acquir Immune Defic Syndr 24: 182-188.
14. Statistics South Africa (2009) Consumer Price Index excluding interest rates on mortgage bonds (CPIX). Available: http://www.statssa.gov.za/ keyindicators/cpix.asp. Accessed 1 May 2008.
15. OANDA.COM: The Currency Site. Available: http://www.oanda.com. Accessed 10 January 2008.
16. Thompson SG, Barber JA (2000) How should cost data in pragmatic randomised trials be analysed? BMJ 320: 1197-1200.
17. Dodd S, Bassi A, Bodger K, Williamson P (2006) A comparison of multivariable regression models to analyse cost data. J Eval Clin Pract 12: 76-86.
18. Microsoft Corporation (2003) Microsoft Access. Redmond (Washington): Microsoft Corporation.
19. StataCorp (2007) Stata Statistical Software: Release 10. College Station (Pennsylvania): StataCorp LP.
20. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
21. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, et al. (2007) Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 146: 564-573.
22. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, et al. (2006) Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 43: 78-84.
23. Gross R, Bilker WB, Wang H, Chapman J (2008) How long is the window of opportunity between adherence failure and virologic failure on efavirenz-based HAART? HIV Clin Trials 9: 202-206.
24. Harling G, Orrell C, Wood R (2007) Healthcare utilization of patients accessing an African national treatment program. BMC Health Serv Res 7: 80.
25. Rosen S, Long L, Sanne I (2008) The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health 13: 1005-1015.
26. Cleary SM, McIntyre D, Boulle AM (2006) The cost-effectiveness of Antiretroviral Treatment in Khayelitsha, South Africa - a primary data analysis. Cost Eff Resour Alloc 4: 20.
27. Rosen S, Long L (2006) How much does it cost to provide antiretroviral therapy for HIV/AIDS in Africa? Boston: Center for International Health and Development, Boston University School of Public Health. pp 1-11.
28. Bozzette SA, Joyce G, McCaffrey DF, Leibowitz AA, Morton SC, et al. (2001) Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 344: 817-823.
29. Aracena B, Gutierrez JP, Bertozzi SM, Gertler P (2005) Cost of AIDS care in Mexico: what are its main individual predictors? Arch Med Res 36: 560-566.
30. Nachega JB, Stein DM, Lehman DA, Hlatshwayo D, Mothopeng R, et al. (2004) Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses 20: 1053-1056.
31. Keiser O, Anastos K, Schechter M, Balestre E, Myer L, et al. (2008) Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 13: 870-879.
32. Westreich D, MacPhail P, Van Riea A, Malope-Kgokongb B, Ive P, et al. (2009) Effect of pulmonary tuberculosis on mortality inpatients receiving HAART. AIDS 23: 707-715.
33. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press.